Sepia Investments Limited, along with persons acting in concert Anchor Partners and Sage Investment Trust, sold a combined 4,580,891 equity shares in Corona Remedies Limited on June 17, 2026. The transaction was executed through the open market on the National Stock Exchange of India Limited (NSE), reducing the sellers' collective stake in the pharmaceutical company.

The disclosures were made to the stock exchanges pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirmed that the sellers do not belong to the promoter or promoter group of Corona Remedies Limited. The total equity share capital of the company remains INR 611,600,880, divided into 61,160,088 equity shares of face value INR 10 each.

Shareholding Details

The sale resulted in a reduction of holdings for all three entities. Sepia Investments Limited sold 4,328,943 shares, while Anchor Partners and Sage Investment Trust offloaded 161,861 and 90,087 shares, respectively.

Regulatory Filing

The disclosure, signed by Panir Pushpom Soobiah, Director of Sepia Investments Limited, and Ashley Menezes, Authorised Signatory for Anchor Partners and Sage Investment Trust, was submitted to BSE Limited and NSE on June 18, 2026. The document detailed the exact percentage changes relative to the total share capital and diluted share capital, which remained unchanged following the disposal.

Corona Remedies Limited has fixed Friday, June 19, 2026, as the record date to determine member entitlement for the dividend for the financial year 2025-26, pending approval at the 22nd Annual General Meeting (AGM). The AGM is scheduled for Thursday, July 8, 2026, at 11:00 a.m. IST via Video Conferencing (VC) and Other Audio Visual Means (OAVM). The company has dispatched the notice and annual report electronically to members with registered email addresses, while others will receive a letter with the weblink to access the documents.

Key AGM and Voting Details

The remote e-voting facility will be available from Monday, July 6, 2026, at 9:00 a.m. to Wednesday, July 8, 2026, at 5:00 p.m. Members holding shares as on the cut-off date of Thursday, July 2, 2026, are entitled to vote. Those who have not cast votes remotely can vote during the AGM via the e-voting system. The final dividend, if declared, will be paid on or before August 7, 2026.

Agenda and Financial Performance

The AGM agenda includes the adoption of audited standalone and consolidated financial statements for FY 2025-26 and the declaration of a final dividend of ₹10 per equity share. The board has proposed the re-appointment of Mr. Nirav Mehta as Managing Director and CEO and the appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors for a term of five years from FY 2026-27 to FY 2030-31.

Corona Remedies reported a revenue of ₹1,403.18 crore for FY 2025-26, a surge of 17.28% from ₹1,196.42 crore in the previous year. Adjusted Profit After Tax (PAT) rose by 33.45% to ₹199.42 crore. The company emerged as the fastest-growing entity in the Top 30 of the Indian Pharmaceutical Market (IPM), with its chronic portfolio contributing 71.94% of revenues.